{"organizations": [], "uuid": "f5a117aeb8e16d7d6916f014f3bfb1ccd164eec9", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 1, "shares": 1, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s2.reutersmedia.net/resources/r/?m=02&d=20180425&t=2&i=1255213201&w=1200&r=LYNXMPEE3O12F", "site_section": "https://www.reuters.com/finance/deals", "section_title": "Deals News | Reuters", "url": "https://www.reuters.com/article/us-shire-m-a-takeda-pharma-gsk/gsk-rules-out-entering-shire-takeover-battle-idUSKBN1HW1JT", "country": "US", "domain_rank": 408, "title": "GSK rules out entering Shire takeover battle", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.036, "site_type": "news", "published": "2018-04-25T20:03:00.000+03:00", "replies_count": 0, "uuid": "f5a117aeb8e16d7d6916f014f3bfb1ccd164eec9"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/us-shire-m-a-takeda-pharma-gsk/gsk-rules-out-entering-shire-takeover-battle-idUSKBN1HW1JT", "ord_in_thread": 0, "title": "GSK rules out entering Shire takeover battle", "locations": [], "entities": {"persons": [{"name": "jason neely", "sentiment": "none"}, {"name": "reuters/loriene perera emma walmsley", "sentiment": "none"}, {"name": "ben hirschler", "sentiment": "none"}], "locations": [{"name": "london", "sentiment": "none"}, {"name": "singapore", "sentiment": "none"}], "organizations": [{"name": "shire", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "glaxosmithkline", "sentiment": "negative"}, {"name": "gsk", "sentiment": "negative"}, {"name": "gsk asia house", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "LONDON (Reuters) - GlaxoSmithKline’s ( GSK.L ) chief executive said on Wednesday she had no interest in acquiring Shire ( SHP.L ), the London-listed rare diseases specialist that Takeda Pharmaceutical ( 4502.T ) hopes to buy for some $64 billion.\nThe GlaxoSmithKline (GSK) logo is seen on top of GSK Asia House in Singapore, March 21, 2018. Picture taken March 21, 2018. REUTERS/Loriene Perera Emma Walmsley, speaking to reporters after first-quarter results, said the British drugmaker’s focus was on deals to acquire early-stage experimental drugs that would help rebuild the company’s pharmaceuticals pipeline.\nReporting by Ben Hirschler; editing by Jason Neely\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-25T20:03:00.000+03:00", "crawled": "2018-04-25T23:13:48.000+03:00", "highlightTitle": ""}